In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Cigna Corp.

With Aduhelm Out Of The Gate, Biogen Focuses On Clearing Commercial Bottlenecks

PET scans and CSF testing to confirm the presence of amyloid beta, and reimbursement, are expected to be early hurdles for launching aducanumab in Alzheimer's.

Launches Approvals

Biogen/Eisai Win On Aduhelm Approval Bet And Wager Next On Price

The first disease modifying drug for Alzheimer's disease will be priced at a $56,000 a year for an average weight patient, setting the drug up to be a mega blockbuster if Biogen can get it reimbursed.

Approvals Launches

ICER Will Explore Link Between Reasonable Drug Pricing And ‘Fair’ US Formulary Policies

Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.

Commercial Market Access

ICER Study On Coverage 'Fairness' Could Inform Manufacturer Pricing vs Benefit Design Debate

Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.

Reimbursement Private Payers
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
UsernamePublicRestriction

Register